[{"id":"18709fb5-d496-4979-9052-5f591bc2f04d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06949033","created_at":"2025-06-28T16:10:58.051Z","updated_at":"2025-06-28T16:10:58.051Z","phase":"Phase 3","brief_title":"Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT06949033","lead_sponsor":"Zuoyi Jiao","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • AiTan (rivoceranib) • oxaliplatin • Kaitanni (cadonilimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 668","initiation":"Initiation: 05/15/2025","start_date":" 05/15/2025","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-04-29"},{"id":"722a2a86-9fad-4d71-874a-87f0351a5eef","acronym":"","url":"https://clinicaltrials.gov/study/NCT06925243","created_at":"2025-06-28T16:10:56.066Z","updated_at":"2025-06-28T16:10:56.066Z","phase":"Phase 3","brief_title":"Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma","source_id_and_acronym":"NCT06925243","lead_sponsor":"Zuoyi Jiao","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • AiTan (rivoceranib) • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 682","initiation":"Initiation: 04/15/2025","start_date":" 04/15/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-04-22"},{"id":"6d7c8fa9-67d2-4bc9-bef1-9bdadb373194","acronym":"","url":"https://clinicaltrials.gov/study/NCT04863430","created_at":"2021-04-28T12:52:46.950Z","updated_at":"2025-02-25T13:49:08.094Z","phase":"Phase 2","brief_title":"Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach","source_id_and_acronym":"NCT04863430","lead_sponsor":"Peking University","biomarkers":" HER-2 • GPC3 • SALL4","pipe":" | ","alterations":" HER-2 positive • HER-2 negative","tags":["HER-2 • GPC3 • SALL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/11/2021","start_date":" 05/11/2021","primary_txt":" Primary completion: 07/06/2023","primary_completion_date":" 07/06/2023","study_txt":" Completion: 07/06/2023","study_completion_date":" 07/06/2023","last_update_posted":"2025-02-21"},{"id":"51bfec9e-786f-4114-83f4-e740501ef39e","acronym":"KEYNOTE-E34","url":"https://clinicaltrials.gov/study/NCT05784688","created_at":"2023-03-27T20:03:27.380Z","updated_at":"2025-02-25T14:09:34.861Z","phase":"Phase 1/2","brief_title":"Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05784688 - KEYNOTE-E34","lead_sponsor":"TiumBio Co., Ltd.","biomarkers":" EGFR • KRAS • BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • HER-2 amplification • BRAF V600 • BRAF wild-type","tags":["EGFR • KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • HER-2 amplification • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • tosposertib (NCE 401)"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 03/10/2023","start_date":" 03/10/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-02-17"},{"id":"fc32aaa3-7f5b-404e-9923-86b9a8cde5d8","acronym":"LUNG-MAP SUB-STUDY","url":"https://clinicaltrials.gov/study/NCT06031688","created_at":"2023-09-11T16:10:36.199Z","updated_at":"2025-02-25T14:10:03.191Z","phase":"Phase 2","brief_title":"Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT06031688 - LUNG-MAP SUB-STUDY","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cyramza (ramucirumab) • Tepmetko (tepotinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 08/08/2024","start_date":" 08/08/2024","primary_txt":" Primary completion: 05/31/2028","primary_completion_date":" 05/31/2028","study_txt":" Completion: 05/31/2029","study_completion_date":" 05/31/2029","last_update_posted":"2025-02-17"},{"id":"d2d9e6c2-1ef0-4919-8d41-0d38872e5bdf","acronym":"Rambro2","url":"https://clinicaltrials.gov/study/NCT05980000","created_at":"2023-08-07T14:09:08.525Z","updated_at":"2025-02-25T17:26:19.610Z","phase":"Phase 2","brief_title":"Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma","source_id_and_acronym":"NCT05980000 - Rambro2","lead_sponsor":"Washington University School of Medicine","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cyramza (ramucirumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 10/27/2023","start_date":" 10/27/2023","primary_txt":" Primary completion: 04/30/2028","primary_completion_date":" 04/30/2028","study_txt":" Completion: 04/30/2031","study_completion_date":" 04/30/2031","last_update_posted":"2025-01-31"},{"id":"b3d0abdf-0279-4d36-aa6d-69fe2e62ba80","acronym":"SHR-1316-SCLC-LN-001","url":"https://clinicaltrials.gov/study/NCT06480864","created_at":"2025-02-26T07:35:04.037Z","updated_at":"2025-02-26T07:35:04.037Z","phase":"","brief_title":"Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer","source_id_and_acronym":"NCT06480864 - SHR-1316-SCLC-LN-001","lead_sponsor":"Yunpeng Liu","biomarkers":" PD-L1 • IL6 • IL10","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • IL6 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • AiTan (rivoceranib) • etoposide IV • AiRuiLi (adebrelimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 08/09/2024","start_date":" 08/09/2024","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-01-06"},{"id":"6ca03c28-cf88-4ab8-8a2b-e94506f71d40","acronym":"","url":"https://clinicaltrials.gov/study/NCT04701060","created_at":"2025-02-26T10:39:27.170Z","updated_at":"2025-02-26T10:39:27.170Z","phase":"Phase 2","brief_title":"Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma","source_id_and_acronym":"NCT04701060","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiRuiKa (camrelizumab) • AiTan (rivoceranib)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 01/26/2021","start_date":" 01/26/2021","primary_txt":" Primary completion: 03/04/2024","primary_completion_date":" 03/04/2024","study_txt":" Completion: 10/04/2024","study_completion_date":" 10/04/2024","last_update_posted":"2024-12-03"},{"id":"784231b9-195e-4cdb-8b0c-3f60c54cd03b","acronym":"KEYNOTE-098","url":"https://clinicaltrials.gov/study/NCT02443324","created_at":"2021-01-17T17:34:42.987Z","updated_at":"2025-02-25T16:14:44.151Z","phase":"Phase 1","brief_title":"A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer","source_id_and_acronym":"NCT02443324 - KEYNOTE-098","lead_sponsor":"Eli Lilly and Company","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Cyramza (ramucirumab)"],"overall_status":"Completed","enrollment":" Enrollment 175","initiation":"Initiation: 07/29/2015","start_date":" 07/29/2015","primary_txt":" Primary completion: 08/31/2018","primary_completion_date":" 08/31/2018","study_txt":" Completion: 04/12/2022","study_completion_date":" 04/12/2022","last_update_posted":"2024-07-31"},{"id":"23fc48e8-8769-4759-8eb9-b726dad67c99","acronym":"Lung-MAP Non-Matched Sub-Study","url":"https://clinicaltrials.gov/study/NCT03971474","created_at":"2021-01-18T19:32:15.856Z","updated_at":"2024-07-02T16:34:25.767Z","phase":"Phase 2","brief_title":"Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)","source_id_and_acronym":"NCT03971474 - Lung-MAP Non-Matched Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • BRAF • ALK • ROS1","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion","tags":["EGFR • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • gemcitabine • docetaxel • Cyramza (ramucirumab) • pemetrexed • lexatumumab (ETR2-ST01)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 166","initiation":"Initiation: 05/28/2019","start_date":" 05/28/2019","primary_txt":" Primary completion: 04/14/2022","primary_completion_date":" 04/14/2022","study_txt":" Completion: 07/15/2024","study_completion_date":" 07/15/2024","last_update_posted":"2024-06-14"},{"id":"a3319e4d-f4d4-4df9-a108-3d23004da6fb","acronym":"","url":"https://clinicaltrials.gov/study/NCT06043427","created_at":"2023-09-21T15:10:26.808Z","updated_at":"2024-07-02T16:34:26.909Z","phase":"Phase 2","brief_title":"Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma","source_id_and_acronym":"NCT06043427","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Cyramza (ramucirumab) • Ziihera (zanidatamab-hrii)"],"overall_status":"Recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 04/16/2024","start_date":" 04/16/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-06-12"},{"id":"4a5cc8d4-4988-48bd-a23f-3af70e820203","acronym":"Lung-MAP Sub-Study","url":"https://clinicaltrials.gov/study/NCT05642572","created_at":"2022-12-08T14:57:35.488Z","updated_at":"2024-07-02T16:34:27.426Z","phase":"Phase 2","brief_title":"Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)","source_id_and_acronym":"NCT05642572 - Lung-MAP Sub-Study","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" EGFR • MET","pipe":" | ","alterations":" EGFR mutation • MET amplification","tags":["EGFR • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Cyramza (ramucirumab) • Tabrecta (capmatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 05/05/2023","start_date":" 05/05/2023","primary_txt":" Primary completion: 05/31/2026","primary_completion_date":" 05/31/2026","study_txt":" Completion: 05/31/2027","study_completion_date":" 05/31/2027","last_update_posted":"2024-06-11"},{"id":"f5bdf194-d00c-403d-a21d-9ca26dbc205a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03527108","created_at":"2021-01-18T17:22:18.280Z","updated_at":"2025-02-25T14:26:57.061Z","phase":"Phase 2","brief_title":"Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC","source_id_and_acronym":"NCT03527108","lead_sponsor":"Fox Chase Cancer Center","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Cyramza (ramucirumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 10/08/2020","start_date":" 10/08/2020","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-06-06"},{"id":"382b7b1e-7eba-439f-b058-87ca67c09ec9","acronym":"RamAtezo-1","url":"https://clinicaltrials.gov/study/NCT03689855","created_at":"2021-01-18T18:05:11.654Z","updated_at":"2024-07-02T16:35:06.356Z","phase":"Phase 2","brief_title":"Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC","source_id_and_acronym":"NCT03689855 - RamAtezo-1","lead_sponsor":"Washington University School of Medicine","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" EGFR mutation • ALK mutation","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cyramza (ramucirumab)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 06/05/2019","start_date":" 06/05/2019","primary_txt":" Primary completion: 07/16/2021","primary_completion_date":" 07/16/2021","study_txt":" Completion: 04/22/2024","study_completion_date":" 04/22/2024","last_update_posted":"2024-05-02"},{"id":"2496a405-f709-49ff-9442-cc8f42dfeb39","acronym":"RAMOSE","url":"https://clinicaltrials.gov/study/NCT03909334","created_at":"2021-01-18T19:14:34.350Z","updated_at":"2024-07-02T16:35:07.044Z","phase":"Phase 2","brief_title":"Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT03909334 - RAMOSE","lead_sponsor":"Xiuning Le","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • Cyramza (ramucirumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 07/25/2019","start_date":" 07/25/2019","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2024-04-30"},{"id":"eedcfd8a-207e-40d0-9c7b-407fde95960b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03982485","created_at":"2021-01-18T19:34:24.357Z","updated_at":"2024-07-02T16:35:06.857Z","phase":"Phase 2","brief_title":"Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer","source_id_and_acronym":"NCT03982485","lead_sponsor":"RenJi Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • AiTan (rivoceranib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 196","initiation":"Initiation: 10/16/2018","start_date":" 10/16/2018","primary_txt":" Primary completion: 03/29/2023","primary_completion_date":" 03/29/2023","study_txt":" Completion: 03/29/2031","study_completion_date":" 03/29/2031","last_update_posted":"2024-04-30"},{"id":"99425b86-d7f5-4e13-abcd-98632d9960ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT04660760","created_at":"2021-01-19T20:42:30.744Z","updated_at":"2024-07-02T16:35:12.122Z","phase":"Phase 2","brief_title":"Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer","source_id_and_acronym":"NCT04660760","lead_sponsor":"Academic and Community Cancer Research United","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • paclitaxel • Cyramza (ramucirumab) • Lonsurf (trifluridine/tipiracil) • lexatumumab (ETR2-ST01)"],"overall_status":"Recruiting","enrollment":" Enrollment 116","initiation":"Initiation: 06/16/2021","start_date":" 06/16/2021","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2024-04-01"},{"id":"53d80059-10cf-4b1e-809f-d51433276602","acronym":"RELAY","url":"https://clinicaltrials.gov/study/NCT02411448","created_at":"2021-01-17T17:40:04.195Z","updated_at":"2024-07-02T16:35:14.291Z","phase":"Phase 3","brief_title":"A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)","source_id_and_acronym":"NCT02411448 - RELAY","lead_sponsor":"Eli Lilly and Company","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • erlotinib • gefitinib • Cyramza (ramucirumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 545","initiation":"Initiation: 05/06/2015","start_date":" 05/06/2015","primary_txt":" Primary completion: 01/23/2019","primary_completion_date":" 01/23/2019","study_txt":" Completion: 12/16/2024","study_completion_date":" 12/16/2024","last_update_posted":"2024-03-18"},{"id":"e2e18e0d-d872-46fc-9331-6fc0c0e97f5b","acronym":"IMMCO-1","url":"https://clinicaltrials.gov/study/NCT05000294","created_at":"2021-08-11T14:55:29.843Z","updated_at":"2024-07-02T16:35:14.403Z","phase":"Phase 1/2","brief_title":"Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types","source_id_and_acronym":"NCT05000294 - IMMCO-1","lead_sponsor":"University of Florida","biomarkers":" HER-2 • TMB • CD4","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • HR negative + HER-2 positive","tags":["HER-2 • TMB • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • HR negative + HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Fotivda (tivozanib)"],"overall_status":"Recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-15"},{"id":"15519149-5911-4354-ba1c-aa8e98df5dca","acronym":"","url":"https://clinicaltrials.gov/study/NCT03190239","created_at":"2021-01-18T15:43:47.591Z","updated_at":"2024-07-02T16:35:17.221Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients","source_id_and_acronym":"NCT03190239","lead_sponsor":"Xinqiao Hospital of Chongqing","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK fusion • ALK mutation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK fusion • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib) • pemetrexed"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/15/2017","start_date":" 07/15/2017","primary_txt":" Primary completion: 07/30/2020","primary_completion_date":" 07/30/2020","study_txt":" Completion: 07/30/2020","study_completion_date":" 07/30/2020","last_update_posted":"2024-02-28"},{"id":"afe5eda5-b0b2-4528-9023-e2c1d7118027","acronym":"","url":"https://clinicaltrials.gov/study/NCT05905887","created_at":"2023-06-15T17:08:41.962Z","updated_at":"2024-07-02T16:35:17.151Z","phase":"Phase 2","brief_title":"Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor","source_id_and_acronym":"NCT05905887","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • imatinib • sunitinib • AiTan (rivoceranib) • Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 09/06/2023","start_date":" 09/06/2023","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-02-28"},{"id":"fc8f9f8c-9d3c-4931-98d3-4b6c2d9d3361","acronym":"","url":"https://clinicaltrials.gov/study/NCT03792503","created_at":"2021-01-18T18:45:02.069Z","updated_at":"2024-07-02T16:35:17.437Z","phase":"Phase 4","brief_title":"Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen","source_id_and_acronym":"NCT03792503","lead_sponsor":"Xinqiao Hospital of Chongqing","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK fusion • ALK mutation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK fusion • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AiTan (rivoceranib) • pemetrexed"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/01/2019","start_date":" 02/01/2019","primary_txt":" Primary completion: 02/01/2020","primary_completion_date":" 02/01/2020","study_txt":" Completion: 02/01/2022","study_completion_date":" 02/01/2022","last_update_posted":"2024-02-28"},{"id":"3469ad5b-7d28-4a0b-b43f-fec6491951ab","acronym":"TaxRamPem","url":"https://clinicaltrials.gov/study/NCT04340882","created_at":"2021-01-18T21:00:48.928Z","updated_at":"2025-02-25T16:10:10.509Z","phase":"Phase 2","brief_title":"Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade","source_id_and_acronym":"NCT04340882 - TaxRamPem","lead_sponsor":"Emory University","biomarkers":" PD-1","pipe":"","alterations":" ","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • docetaxel • Cyramza (ramucirumab) • lexatumumab (ETR2-ST01)"],"overall_status":"Recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 06/05/2020","start_date":" 06/05/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2024-02-13"},{"id":"aa38eeda-5483-4291-b2f6-f2732467a0db","acronym":"SYSKY-2023-1016-01","url":"https://clinicaltrials.gov/study/NCT06255392","created_at":"2024-02-14T01:28:08.463Z","updated_at":"2024-07-02T16:35:19.550Z","phase":"Phase 3","brief_title":"Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer","source_id_and_acronym":"NCT06255392 - SYSKY-2023-1016-01","lead_sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","biomarkers":" BRCA","pipe":"","alterations":" ","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • paclitaxel • AiTan (rivoceranib) • capecitabine • Halaven (eribulin mesylate) • AiRuiYi (fluzoparib) • Navelbine oral (vinorelbine tartrate oral)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 03/01/2031","primary_completion_date":" 03/01/2031","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2024-02-13"}]